Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells $17,413.44 in Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CEO Quang Pham sold 3,298 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $5.28, for a total transaction of $17,413.44. Following the sale, the chief executive officer directly owned 185,150 shares in the company, valued at approximately $977,592. This represents a 1.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Price Performance

Shares of NASDAQ:CVKD opened at $4.96 on Monday. Cadrenal Therapeutics, Inc. has a 12 month low of $4.21 and a 12 month high of $15.99. The company’s 50-day moving average price is $5.31 and its two-hundred day moving average price is $7.15. The firm has a market cap of $14.24 million, a P/E ratio of -0.88 and a beta of 1.60.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.47. As a group, equities analysts predict that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. DRW Securities LLC acquired a new position in Cadrenal Therapeutics during the 4th quarter valued at about $171,000. Citadel Advisors LLC acquired a new position in Cadrenal Therapeutics during the 3rd quarter valued at about $274,000. Geode Capital Management LLC lifted its position in Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after purchasing an additional 1,818 shares during the period. Finally, JPMorgan Chase & Co. acquired a new position in Cadrenal Therapeutics during the 3rd quarter valued at about $103,000. 7.92% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on CVKD. Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Monday, April 20th. HC Wainwright cut their target price on shares of Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Finally, Wall Street Zen upgraded shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.